Physician profile
Don W Shaffer
NPI 1124023452
$4,880.01
in general payments reported to CMS, 2019-2025
38 companies · $80.78 in 2025
The $80.78 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $1,511 · 2021: $2,271 · 2022: $206 · 2023: $120 · 2025: $80.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,580.83 | 2021 | |
| Rigel Pharmaceuticals, INC. | $1,018.66 | 2020 | |
| Seagen INC. | $201.81 | 2019-2023 | Tukysa |
| Pfizer INC. | $191.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $150.95 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Genentech USA, INC. | $132.67 | 2019-2023 | Venclexta |
| Astellas Pharma US INC | $112.37 | 2020-2022 | |
| Amgen INC. | $107.68 | 2019-2022 | |
| Abbvie INC. | $107.29 | 2022-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Celgene Corporation | $76.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $69.15 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $66.32 | 2019-2020 | |
| Exelixis INC. | $65.42 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $65.37 | 2019-2021 | |
| Janssen Biotech, INC. | $58.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $53.64 | 2019-2020 | |
| Genentech, INC. | $49.95 | 2021 | |
| Clovis Oncology, INC. | $48.04 | 2019-2020 | |
| Eisai INC. | $47.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.41 | 2019-2020 | |
| Blueprint Medicines Corporation | $40.16 | 2020 | |
| Array Biopharma INC | $40.00 | 2021 | |
| Foundation Medicine, INC. | $36.21 | 2023 | Foundationone Liquid Cdx |
| Beigene USA, INC. | $32.96 | 2020-2021 | |
| Kyowa Kirin, INC. | $27.64 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $25.49 | 2022 | |
| Daiichi Sankyo INC. | $23.80 | 2023 | Injectafer |
| Tersera Therapeutics LLC | $23.12 | 2021 | |
| Glaxosmithkline, LLC. | $23.05 | 2021 | |
| Verastem, INC. | $18.13 | 2019 | |
| Genzyme Corporation | $17.87 | 2019 | |
| Epizyme, INC. | $17.42 | 2022 | |
| Lilly USA, LLC | $16.67 | 2021 | |
| Mylan Institutional INC. | $15.20 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.21 | 2022 | |
| Emd Serono, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.